{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:36:53Z","timestamp":1760747813587,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"3-5","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.jsbmb.2006.12.089","type":"journal-article","created":{"date-parts":[[2006,12,28]],"date-time":"2006-12-28T07:06:58Z","timestamp":1167289618000},"page":"578-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Vitamin D analogs for secondary hyperparathyroidism: What does the future hold?"],"prefix":"10.1016","volume":"103","author":[{"given":"Alex J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2006.12.089_bib1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3177\/jnsv.35.529","article-title":"Protein-binding properties of 22-oxa-1\u03b1,25-dihydroxyvitamin D3, a synthetic analogue of 1\u03b1,25-dihydroxyvitamin D3","volume":"35","author":"Okano","year":"1989","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/endo-128-4-1687","article-title":"On the mechanisms for the selective action of vitamin D analogs","volume":"128","author":"Dusso","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2006.12.089_bib5","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/endo.133.3.8396012","article-title":"The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine","volume":"133","author":"Brown","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2006.12.089_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.jbchem.a124346","article-title":"The binding properties, with blood proteins, and tissue distribution of 22-oxa-1\u03b1,25-dihydroxyvitamin D3, a noncalcemic analogue of 1\u03b1, 25-dihydroxyvitamin D3, in rats","volume":"115","author":"Kobayashi","year":"1994","journal-title":"J. Biochem."},{"issue":"Suppl. 29","key":"10.1016\/j.jsbmb.2006.12.089_bib7","first-page":"S22","article-title":"New active analogues of vitamin D with low calcemic activity","volume":"29","author":"Brown","year":"1990","journal-title":"Kidney Int."},{"issue":"Suppl. 10","key":"10.1016\/j.jsbmb.2006.12.089_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ndt\/17.suppl_10.53","article-title":"In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue [3H]1,25-dihydroxy-22-oxavitamin D3 compared to [3H]1,25-dihydroxyvitamin D3, determined by micro-autoradiography","volume":"17","author":"Koike","year":"2002","journal-title":"Nephol. Dial. Transplant."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/MCB.19.2.1049","article-title":"Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog","volume":"19","author":"Takeyama","year":"1999","journal-title":"Mol. Cell. Biol."},{"issue":"Suppl. 10","key":"10.1016\/j.jsbmb.2006.12.089_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_10.28","article-title":"Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study","volume":"17","author":"Akizawa","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib11","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/ndt\/gfh329","article-title":"Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial","volume":"19","author":"Hayashi","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1\u03b1,25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib13","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","article-title":"Therapy of secondary hyperparathyroidism with 19-nor-1\u03b1,25-dihydroxyvitamin D2","volume":"32","author":"Martin","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib14","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in patients with calcitriol-resistent secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib15","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol","volume":"38","author":"Sprague","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1\u03b1-Hydroxyvitamin D2 is less toxic than 1\u03b1-hydroxyvitamin D3 in the rat","volume":"178","author":"Sjoden","year":"1985","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1\u03b1-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/13.suppl_3.68","article-title":"Intermittent oral 1\u03b1hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients","volume":"3","author":"Frazao","year":"1998","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1\u03b1-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison","volume":"37","author":"Maung","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib21","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1523-1755.2002.kid573.x","article-title":"Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats","volume":"62","author":"Slatopolsky","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib22","first-page":"495A","article-title":"Differential effects of paricalcitol and doxercalciferol on serum PTH and ionized calcium in uremic rats with established secondary hyperparathyroidism","volume":"16","author":"Reinhart","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/dmd.31.8.973","article-title":"Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds","volume":"31","author":"Komuro","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib26","first-page":"7","article-title":"1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect","volume":"61","author":"Lippuner","year":"2004","journal-title":"Horm. Res."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jcb.20553","article-title":"Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D(3), a potent suppressor of parathyroid hormone secretion","volume":"96","author":"Brown","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib28","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1073\/pnas.0401656101","article-title":"Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl","volume":"101","author":"Plum","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jsbmb.2006.12.089_bib29","article-title":"A new vitamin D analog without calcemic and phosphatemic effects","volume":"14","author":"Slatopolsky","year":"2003","journal-title":"J. Am. Soc. Nephol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/11.supp3.22","article-title":"A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism","volume":"11","author":"Martinez","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1053\/snep.2002.35965","article-title":"Renal osteodystrophy in chronic renal failure","volume":"22","author":"Ho","year":"2002","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib32","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archinte.1980.00330190042017","article-title":"Effects of long-term therapy with calcitriol in patients with moderate renal failure","volume":"140","author":"Healy","year":"1980","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib36","first-page":"2967","article-title":"25-Hydroxyvitamin D3-1\u03b1-hydroxylase expression in normal and pathological parathyroid glands","volume":"87","author":"Segersten","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib37","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1210\/jc.2002-021356","article-title":"Increased 25-hydroxyvitamin D3 1\u03b1-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase in parathyroid tumors\u2014new prospects for treatment of hyperparathyroidism with vitamin D","volume":"87","author":"Correa","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib38","first-page":"750A","article-title":"25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by cultured bovine parathyroid cells: potential role for intracrine 1,25-dihydroxyvitamin D3","volume":"16","author":"Ritter","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","article-title":"RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone","volume":"55","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib40","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1368-5031.2005.00592.x","article-title":"Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients","volume":"59","author":"Albaaj","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib41","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.mnh.0000172722.52499.71","article-title":"Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?","volume":"14","author":"Goodman","year":"2005","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib45","first-page":"279A","article-title":"Survival among hemodialysis patients receiving intravenous doxercalciferol and paricalcitol versus calcitriol","volume":"16","author":"Tentori","year":"2005","journal-title":"J. Am. Soc. Nephol."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib46","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jsbmb.2006.12.089_bib47","first-page":"279A","article-title":"Decreased odds of hospitalization among hemodialysis patients receiving doxercalciferol and paricalcitol versus calcitriol","volume":"16","author":"Tentori","year":"2005","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076006004559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076006004559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:53:29Z","timestamp":1760734409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076006004559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":47,"journal-issue":{"issue":"3-5","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0960076006004559"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2006.12.089","relation":{},"ISSN":["0960-0760"],"issn-type":[{"type":"print","value":"0960-0760"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitamin D analogs for secondary hyperparathyroidism: What does the future hold?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2006.12.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}